NO20010603D0 - 2-substituert-1-piperidylbenzimidazol forbindelser som ORL 1- reseptor agonister - Google Patents

2-substituert-1-piperidylbenzimidazol forbindelser som ORL 1- reseptor agonister

Info

Publication number
NO20010603D0
NO20010603D0 NO20010603A NO20010603A NO20010603D0 NO 20010603 D0 NO20010603 D0 NO 20010603D0 NO 20010603 A NO20010603 A NO 20010603A NO 20010603 A NO20010603 A NO 20010603A NO 20010603 D0 NO20010603 D0 NO 20010603D0
Authority
NO
Norway
Prior art keywords
piperidylbenzimidazole
orl
substituted
compounds
receptor agonists
Prior art date
Application number
NO20010603A
Other languages
English (en)
Other versions
NO20010603L (no
Inventor
Fumitaka Ito
Hirohide Noguchi
Hiroshi Kondo
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO20010603D0 publication Critical patent/NO20010603D0/no
Publication of NO20010603L publication Critical patent/NO20010603L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20010603A 1998-08-06 2001-02-05 2-substituert-1-piperidylbenzimidazol forbindelser som ORL 1- reseptor agonister NO20010603L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IBPCT/IB98/01206 1998-08-06
PCT/IB1999/001239 WO2000008013A2 (en) 1998-08-06 1999-07-05 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists

Publications (2)

Publication Number Publication Date
NO20010603D0 true NO20010603D0 (no) 2001-02-05
NO20010603L NO20010603L (no) 2001-04-05

Family

ID=11004738

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010603A NO20010603L (no) 1998-08-06 2001-02-05 2-substituert-1-piperidylbenzimidazol forbindelser som ORL 1- reseptor agonister

Country Status (44)

Country Link
US (1) US6172067B1 (no)
EP (1) EP1102762B1 (no)
JP (1) JP3367945B2 (no)
CN (1) CN1317968A (no)
AP (1) AP2001002063A0 (no)
AR (1) AR018686A1 (no)
AT (1) ATE227716T1 (no)
AU (1) AU749166B2 (no)
BG (1) BG105301A (no)
BR (1) BR9912778A (no)
CA (1) CA2339621C (no)
CZ (1) CZ2001397A3 (no)
DE (1) DE69903953T2 (no)
DK (1) DK1102762T3 (no)
EA (1) EA200100104A1 (no)
EE (1) EE200100075A (no)
ES (1) ES2185357T3 (no)
GE (1) GEP20033000B (no)
GT (1) GT199900125A (no)
HK (1) HK1040188A1 (no)
HN (1) HN1999000105A (no)
HR (1) HRP20010089B1 (no)
HU (1) HUP0103567A3 (no)
ID (1) ID27212A (no)
IL (1) IL141029A0 (no)
IS (1) IS5812A (no)
MA (1) MA26659A1 (no)
NO (1) NO20010603L (no)
NZ (1) NZ509299A (no)
OA (1) OA11590A (no)
PA (1) PA8477701A1 (no)
PE (1) PE20000868A1 (no)
PL (1) PL346211A1 (no)
PT (1) PT1102762E (no)
SI (1) SI1102762T1 (no)
SK (1) SK1602001A3 (no)
SV (1) SV1999000099A (no)
TN (1) TNSN99142A1 (no)
TR (1) TR200100403T2 (no)
TW (1) TW513424B (no)
UY (1) UY25659A1 (no)
WO (1) WO2000008013A2 (no)
YU (1) YU8201A (no)
ZA (1) ZA200100900B (no)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6340681B1 (en) * 1999-07-16 2002-01-22 Pfizer Inc 2-benzimidazolylamine compounds as ORL-1-receptor agonists
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
ES2249237T3 (es) 2000-01-05 2006-04-01 Pfizer Inc. Compuestos de bencimidazol como antagonistas del receptor orl1.
GB2359078A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB0005642D0 (en) 2000-03-10 2000-05-03 Astrazeneca Uk Ltd Chemical compounds
SE0003828D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
CA2428787A1 (en) * 2000-11-15 2002-05-23 Banyu Pharmaceutical Co., Ltd. Benzimidazole derivatives
GB0104050D0 (en) 2001-02-19 2001-04-04 Astrazeneca Ab Chemical compounds
GB0107228D0 (en) 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
KR100722207B1 (ko) * 2001-04-18 2007-05-29 유로-셀티크 소시에떼 아노뉨 노시셉틴 유사체
JP4401076B2 (ja) 2001-04-18 2010-01-20 ユーロ−セルティーク エス．エイ． ベンズイミダゾロン化合物
SI1598339T1 (sl) * 2001-04-18 2009-12-31 Euro Celtique Sa Derivati 1-(4-amino.cikloheksil)-1,3-dihidro-2h-benzimidazol-2-ona in sorodne spojine kot nociceptinski analogi in ORL1 ligandi za zdravljenje bolečine
SI1385514T1 (sl) 2001-04-18 2009-04-30 Euro Celtique Sa Spiroindenske in spiroindanske spojine
HUP0401333A3 (en) 2001-04-18 2004-11-29 Euro Celtique Sa Spiropyrazole compounds and pharmaceutical compositions containing them
US20030040479A1 (en) * 2001-07-02 2003-02-27 Omeros Corporation Rotational intrathecal analgesia method and device
EP1406629A1 (en) * 2001-07-02 2004-04-14 Omeros Corporation Method for inducing analgesia comprising administration alternatively of an opioid receptor agonist and an opioid receptor like receptor 1 agonist for and an implantable infusion pump
SE0102716D0 (sv) * 2001-08-14 2001-08-14 Astrazeneca Ab Novel compounds
SE0103818D0 (sv) * 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
WO2003049736A1 (en) * 2001-12-11 2003-06-19 Sepracor, Inc. 4-substituted piperidines, and methods of use thereof
DK1491212T3 (da) 2002-03-29 2012-10-29 Mitsubishi Tanabe Pharma Corp Middel til behandling af søvnforstyrrelser
GB0221829D0 (en) * 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
DE10252665A1 (de) * 2002-11-11 2004-06-03 Grünenthal GmbH 4-Aminomethyl-1-aryl-cyclohexylamin-Derivate
DE10252666A1 (de) 2002-11-11 2004-08-05 Grünenthal GmbH N-Piperidyl-cyclohexan-Derivate
GB0315203D0 (en) * 2003-06-28 2003-08-06 Celltech R&D Ltd Chemical compounds
AR045939A1 (es) 2003-09-25 2005-11-16 Solvay Pharm Bv Derivados de bencimidazolona y quinazolinona como agonistas de los receptores orl 1 humanos
GB0328243D0 (en) * 2003-12-05 2004-01-07 Astrazeneca Ab Methods
US20050228023A1 (en) * 2003-12-19 2005-10-13 Sri International Agonist and antagonist ligands of the nociceptin receptor
CA2583326A1 (en) * 2004-10-08 2006-04-13 Takeda Pharmaceutical Company Limited Receptor function regulating agent
DE602006018255D1 (de) 2005-01-11 2010-12-30 Neurosearch As Neue 2-amino-benzimidazolderivate und ihre verwendung als modulatoren calciumaktivierter kaliumkanäle mit geringer leitfähigkeit
AU2007271243A1 (en) * 2006-07-03 2008-01-10 Neurosearch A/S Combinations of monoamine reuptake inhibitors and potassium channel activators
NZ578078A (en) 2007-01-16 2011-11-25 Purdue Pharma Lp Heterocyclic-substituted piperidine as orl-1 ligands
JP5554709B2 (ja) * 2007-08-31 2014-07-23 パーデュー、ファーマ、リミテッド、パートナーシップ 置換キノキサリンタイプピペリジン化合物とその使用
US8119661B2 (en) * 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
PE20140102A1 (es) 2008-07-21 2014-02-06 Purdue Pharma Lp Compuestos de piperidina puenteada tipo quinoxalina sustituida con actividad sobre el receptor orl-1
SG187209A1 (en) 2010-08-05 2013-03-28 Amgen Inc Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase
JP6007262B2 (ja) 2012-01-06 2016-10-12 ノーバス・インターナショナル・インコーポレイテッドＮｏｖｕｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ，Ｉｎｃ． スルホキシドベース界面活性剤
WO2013119959A1 (en) 2012-02-09 2013-08-15 Novus International Inc. Heteroatom containing cyclic dimers
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
EP2871973B1 (en) 2012-07-12 2018-10-03 Novus International Inc. Matrix and layer compositions for protection of bioactives
US9085561B2 (en) * 2012-07-30 2015-07-21 Purdue Pharma L.P. Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators
WO2014102594A2 (en) * 2012-12-27 2014-07-03 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
US9656994B2 (en) 2013-03-22 2017-05-23 The Scripps Research Institute Substituted benzimidazoles as nociceptin receptor modulators
CA2943220C (en) 2014-03-20 2024-01-16 Capella Therapeutics, Inc. Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
AU2016353076A1 (en) 2015-11-12 2018-05-10 Novus International Inc. Sulfur-containing compounds as solvents
US10584306B2 (en) 2017-08-11 2020-03-10 Board Of Regents Of The University Of Oklahoma Surfactant microemulsions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3318900A (en) * 1964-05-06 1967-05-09 Janssen Pharmaceutica Nv Derivatives of benzimidazolinyl piperidine
JPS5297978A (en) * 1976-06-02 1977-08-17 Yoshitomi Pharmaceut Ind Ltd Preparation of alicyclic derivatives
US5821219A (en) 1995-08-11 1998-10-13 Oregon Health Sciences University Opioid antagonists and methods of their use
JP4191796B2 (ja) 1995-08-15 2008-12-03 ユーロスクリーン・ソシエテ・アノニム 拮抗剤または作動剤として、ヒトｏｒｌ１受容体に結合できることが知られていない化合物を回収する方法
US5866346A (en) 1995-09-27 1999-02-02 Indiana Unversity Foundation Methods of using dynorphins as ligands for XOR1 receptor
ATE341542T1 (de) * 1996-04-19 2006-10-15 Neurosearch As 1-(4-piperidyl)-benzimidazole mit neurotropher aktivität
EP0813065A3 (en) 1996-06-13 1998-07-22 F. Hoffmann-La Roche Ag Modulation of LC132 (opioid-like) receptor function
EP0829481A1 (en) * 1996-09-16 1998-03-18 Pfizer Inc. Morphinan hydroxamic acid compounds
US5718912A (en) * 1996-10-28 1998-02-17 Merck & Co., Inc. Muscarine agonists
ES2226129T3 (es) 1997-05-30 2005-03-16 Banyu Pharmaceutical Co., Ltd. Derivados de 2-0x0imidazol.
AU8334298A (en) 1997-07-15 1999-02-10 Novo Nordisk A/S Nociceptin analogues
US5929035A (en) 1998-04-14 1999-07-27 Regents Of The University Of Michigan Methods of treating intestinal disorders
ID29137A (id) 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1

Also Published As

Publication number Publication date
AU749166B2 (en) 2002-06-20
GT199900125A (es) 2001-01-27
IL141029A0 (en) 2002-02-10
ES2185357T3 (es) 2003-04-16
EP1102762B1 (en) 2002-11-13
HRP20010089B1 (en) 2003-04-30
TW513424B (en) 2002-12-11
EP1102762A2 (en) 2001-05-30
HN1999000105A (es) 2000-11-11
CA2339621A1 (en) 2000-02-17
DE69903953D1 (de) 2002-12-19
DK1102762T3 (da) 2002-12-16
WO2000008013A2 (en) 2000-02-17
ATE227716T1 (de) 2002-11-15
ID27212A (id) 2001-03-08
DE69903953T2 (de) 2003-03-27
HUP0103567A3 (en) 2003-01-28
EE200100075A (et) 2002-06-17
MA26659A1 (fr) 2004-12-20
OA11590A (en) 2004-08-18
TNSN99142A1 (fr) 2005-11-10
SV1999000099A (es) 2000-09-05
UY25659A1 (es) 2000-02-23
EA200100104A1 (ru) 2001-08-27
AR018686A1 (es) 2001-11-28
CN1317968A (zh) 2001-10-17
GEP20033000B (en) 2003-06-25
JP2002522431A (ja) 2002-07-23
TR200100403T2 (tr) 2001-07-23
NO20010603L (no) 2001-04-05
JP3367945B2 (ja) 2003-01-20
HK1040188A1 (zh) 2002-05-31
AP2001002063A0 (en) 2001-03-31
CA2339621C (en) 2005-04-05
PT1102762E (pt) 2003-02-28
YU8201A (sh) 2003-07-07
PL346211A1 (en) 2002-01-28
AU4385999A (en) 2000-02-28
HUP0103567A2 (hu) 2002-02-28
BR9912778A (pt) 2001-09-25
PE20000868A1 (es) 2000-08-31
HRP20010089A2 (en) 2002-02-28
NZ509299A (en) 2003-05-30
SI1102762T1 (en) 2003-04-30
US6172067B1 (en) 2001-01-09
SK1602001A3 (en) 2002-09-10
WO2000008013A3 (en) 2000-03-23
ZA200100900B (en) 2002-08-28
BG105301A (en) 2001-12-29
CZ2001397A3 (cs) 2002-05-15
PA8477701A1 (es) 2000-09-29
IS5812A (is) 2001-01-16

Similar Documents

Publication Publication Date Title
NO20010603D0 (no) 2-substituert-1-piperidylbenzimidazol forbindelser som ORL 1- reseptor agonister
NO20001141D0 (no) Aromatisk C16-C20-substituert tetrahydro-prostaglandiner anvendbare som FP-agonister
HK1041486A1 (zh) 作為***素e2激動劑或拮抗劑的噁唑化合物
ATE435861T1 (de) 12,13-cyclopropan-epothilonderivate
ID24836A (id) Agonis prostaglandin
NO20001139D0 (no) Aromatisk C16-C20-substituert tetrahydro-prostaglandiner anvendbare som FP-agonister
NO20001142L (no) Aromatisk C16-C20-substituert tetrahydro-prostaglandiner anvendbare som FP-agonister
ID25548A (id) Senyawa-senyawa heterosiklik spiroazabisiklik terbaru
DK1000048T3 (da) Substituerede 1,2,3,4-tetrahydronapthalenderivater
EE200100145A (et) Opioidiretseptoriga koos toimivad 4,4-biarüülpiperidiini derivaadid
DK0975623T3 (da) Indazolamidforbindelser som sertoninerge midler
DK1068202T3 (da) 1-(-heteroarylpropyl- eller -prop-2-enyl)-4benzylpipderidiner som NMDA-receptor-antagonister
NO992470D0 (no) 2-amidazolinyl-amino-indolforbindelser anvendelige som <alfa>-2-adreno-reseptoragonister
NO20002036L (no) Cyklopentenderivater anvendbare som antagonister for motilinreseptoren
ID21009A (id) Komposisi untuk supositori
DK0708105T3 (da) 5-HT4-receptoragonister
ATE204279T1 (de) Diaza-spiro(3,5)nonan-derivate
EE200000447A (et) 1,3,4-oksadiasolooni derivaadid
NO985970L (no) Indolinderivater anvendelige som 5_HT-2C-reseptor-antagonister
NO985972D0 (no) Indolinderivater anvendelige som 5-HT-2C reseptorantagonister
NO993812D0 (no) (4-piperidinyl)-1H-2benzopyranderivater som er anvendbare som antipsykotiske midler
DK0944601T3 (da) Heterocykliske quanidinylaminoforbindelser som alfa-2-adrenoceptoragonister
NO992502D0 (no) 2-Imidazolinylaminoindazolforbindelser nyttige som <alfa>-2 adrenerge reseptoragonister
NO20002575D0 (no) Substituerte oksimer som neurokininantagonister
ES1039293Y (es) Brazo para la fijacion de estructuras.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application